U.S. patent application number 11/435015 was filed with the patent office on 2006-11-30 for controlled release tramadol formulations.
This patent application is currently assigned to Euro-Celtique S.A.. Invention is credited to Ronald Brown Miller, Udo Hahn, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Kevin John Smith, Walter Wimmer, Horst Winkler.
Application Number | 20060269603 11/435015 |
Document ID | / |
Family ID | 27435744 |
Filed Date | 2006-11-30 |
United States Patent
Application |
20060269603 |
Kind Code |
A1 |
Brown Miller; Ronald ; et
al. |
November 30, 2006 |
Controlled release tramadol formulations
Abstract
A controlled release preparation for oral administration
contains tramadol, or a pharmaceutically acceptable salt thereof,
as active ingredient.
Inventors: |
Brown Miller; Ronald;
(Basic, CH) ; Leslie; Stewart Thomas; (Cambridge,
GB) ; Malkowska; Sandra Therese Antoinette;
(Cambridge, GB) ; Smith; Kevin John; (Cambridge,
GB) ; Wimmer; Walter; (Limburg, DE) ; Winkler;
Horst; (Linter, DE) ; Hahn; Udo;
(Nentersflausen, DE) ; Prater; Derek Allan;
(Cambridge, GB) |
Correspondence
Address: |
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 SEVENTH AVENUE, 14TH FLOOR
NEW YORK
NY
10018
US
|
Assignee: |
Euro-Celtique S.A.
Luxembourg
LU
|
Family ID: |
27435744 |
Appl. No.: |
11/435015 |
Filed: |
May 16, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09800204 |
Mar 6, 2001 |
7074430 |
|
|
11435015 |
May 16, 2006 |
|
|
|
08677798 |
Jul 10, 1996 |
6254887 |
|
|
09800204 |
Mar 6, 2001 |
|
|
|
08241129 |
May 10, 1994 |
5591452 |
|
|
08677798 |
Jul 10, 1996 |
|
|
|
Current U.S.
Class: |
424/468 |
Current CPC
Class: |
A61K 9/1617 20130101;
A61K 9/2077 20130101; A61P 29/02 20180101; A61K 9/2054 20130101;
A61P 23/00 20180101; A61K 31/485 20130101; A61K 9/2095 20130101;
A61P 25/04 20180101; A61K 31/137 20130101; A61K 9/2072 20130101;
A61K 9/1652 20130101; A61K 9/2013 20130101; A61K 9/2031 20130101;
A61K 9/1641 20130101; A61K 31/135 20130101; A61K 9/2866
20130101 |
Class at
Publication: |
424/468 |
International
Class: |
A61K 9/22 20060101
A61K009/22 |
Foreign Application Data
Date |
Code |
Application Number |
May 10, 1993 |
DE |
P4315525.1 |
Nov 23, 1993 |
GB |
9324045.5 |
Mar 9, 1994 |
GB |
9404544.4 |
Mar 14, 1994 |
GB |
9404928.5 |
Claims
1-41. (canceled)
42. A solid controlled release oral dosage form, comprising: a
therapeutically effective amount of tramadol or a pharmaceutically
acceptable salt thereof incorporated into a controlled release
matrix, said controlled release matrix comprising an alkylcellulose
or an acrylic resin or a mixture thereof; said dosage form
providing a therapeutic effect for at least about 24 hours.
43. The controlled release dosage form as claimed in claim 42,
wherein said controlled release matrix comprises a
polymethacrylate.
44. The controlled release dosage form as claimed in claim 42,
wherein said controlled release matrix comprises a water insoluble
cellulose.
45. The controlled release dosage form as claimed in claim 43,
wherein said controlled release matrix further comprises a water
soluble cellulose.
46. The controlled release dosage form as claimed in claim 44,
wherein said controlled release matrix further comprises a
polyvinylpyrrolidone.
47. The controlled release dosage form as claimed in claim 42,
comprising from about 50 to 800 mg of tramadol or a
pharmaceutically acceptable salt thereof, calculated as the
hydrochloride salt.
48. The controlled release dosage form as claimed in claim 42,
having a dissolution rate in-vitro when measured using the Ph. Eur.
Paddle Method at 100 rpm in 900 ml 0.1N hydrochloric acid at
37.degree. C. and using UV detection at 270 nm, from about 0 to
about 50% tramadol released after 1 hour; from about 0 to about 75%
tramadol released after 2 hours; from about 10 to about 95%
tramadol released after 4 hours; from about 35 to about 100% after
8 hours; from about 55 to about 100% tramadol released after 12
hours; from about 70 to about 100% tramadol released after 16
hours; and greater than 90% tramadol released after 24 hours, by
weight.
49. The controlled release dosage form as claimed in claim 42,
having a dissolution rate in-vitro when measured using the Ph. Eur.
Paddle Method at 100 rpm in 900 ml 0.1N hydrochloric acid at
37.degree. C. and using UV detection at 270 nm, from about 0 to
about 30% tramadol released after 1 hour; from about 0 to about 40%
tramadol released after 2 hours; from about 3 to about 55% tramadol
released after 4 hours; from about 10 to about 65% after 8 hours;
from about 20 to about 75% tramadol released after 12 hours; from
about 30 to about 88% tramadol released after 16 hours; from about
50 to about 100% tramadol released after 24 hours and greater than
80% tramadol released after 36 hours, by weight.
50. The controlled release dosage form as claimed in claim 42,
having a dissolution rate in-vitro when measured using the Ph. Eur.
Paddle Method at 100 rpm in 900 ml 0.1N hydrochloric acid at
37.degree. C. and using UV detection at 270 nm, from about 15 to
about 25% tramadol released after 1 hour; from about 25 to about
35% tramadol released after 2 hours; from about 30 to about 45%
tramadol released after 4 hours; from about 40 to about 60% after 8
hours; from about 55 to about 70% tramadol released after 12 hours;
and from about 60 to about 75% tramadol released after 16 hours, by
weight.
51. The dosage form according to claim 42, which provides a
T.sub.max from about 3 to about 6 hours.
52. The dosage form according to claim 42, which provides a
W.sub.50 from about 10 to about 33 hours.
53. The dosage form according to claim 44 wherein said water
insoluble cellulose comprises ethylcellulose.
54. The dosage form of claim 42, comprising 100 mg tramadol
hydrochloride.
55. The dosage form of claim 42, comprising 200 mg tramadol
hydrochloride.
56. The dosage form of claim 42, comprising 300 mg tramadol
hydrochloride.
57. The dosage form of claim 42, comprising 400 mg tramadol
hydrochloride.
58. The dosage form of claim 42, comprising 600 mg tramadol
hydrochloride.
59. The dosage form of claim 42, further comprising a coating.
60. The dosage form of claim 59, wherein the coating is a film
coating.
61. The dosage form of claim 42, wherein said controlled release
matrix is in a form of multiparticulates.
Description
[0001] This application is a continuation of U.S. patent
application Ser. No. 09/800,204 filed on Mar. 6, 2001; which is a
continuation of U.S. patent application Ser. No. 08/677,798, filed
Jul. 10, 1996 (now U.S. Pat. No. 6,254,887); which is a
continuation of U.S. patent application Ser. No. 08/241,129, filed
May 10, 1994 (now U.S. Pat. No. 5,591,452).
[0002] The present invention relates to a controlled release
preparation for oral administration, to processes for its
preparation and to its medical use. In particular, the invention
relates to a controlled release preparation comprising tramadol or
a pharmaceutically acceptable salt thereof.
[0003] Tramadol, which has the chemical name
([.+-.])-trans-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)
cyclohexanol, is an orally active opioid analgesic. Conventional
release preparations in the form of capsules, drops and
suppositories containing tramadol, or more particularly its
hydrochloride salt, have been commercially available for many years
for use in the treatment of moderate to severe pain; Such
preparations, however, do not provide a controlled release of the
tramadol. Moreover, despite tramadol's long-standing use,
controlled release preparations for oral administration containing
tramadol as active ingredient have not even previously been
described in the literature.
[0004] It is an object of the present invention to provide an oral
controlled release tramadol preparation suitable for at least
twelve-hourly (e.g. up to twenty-four hourly) administration for
the treatment of pain.
[0005] The present invention therefore provides a controlled
release preparation comprising tramadol or a pharmaceutically
acceptable salt therefor for oral administration.
[0006] Suitable pharmaceutically acceptable salts of tramadol for
use according to the present invention are those conventionally
known in the art such as pharmaceutically acceptable acid addition
salts. The hydrochloride salt is particularly preferred.
[0007] A controlled release preparation according to the present
invention is one that achieves slow release of a drug over an
extended period of time, thereby extending the duration of drug
action over that achieved by conventional delivery. Preferably such
a preparation maintains a drug concentration in the blood within
the therapeutic range for 12 hours or more.
[0008] The present inventors have found that in order to allow for
controlled release tramadol over at least a tweleve hour period
following oral administration, the in vitro release rate preferably
corresponds to the following % rate of tramadol released:
TABLE-US-00001 TABLE 1 TIME (H) % RELEASED 1 0-50 2 0-75 3 3-95 8
10-100 12 20-100 16 30-100 24 50-100 36 >80
[0009] Another preferred preparation especially suited for
twice-a-day dosing has an in vitro release rate corresponding to
the following % rate of tramadol released: TABLE-US-00002 TABLE 2
TIME (H) % RELEASED 1 20-50 2 40-75 3 60-95 8 80-100 12 90-100
[0010] Yet another preferred paration particularly suited for
once-a-day dosing has an in-vitro release rate corresponding to the
following % rate of tramadol released: TABLE-US-00003 TABLE 3 TIME
(H) % RELEASED 1 0-50 2 0-75 3 10-95 8 35-100 12 55-100 16 70-100
24 >90
[0011] A still further preparation in accordance with the invention
also particularly suited for once-a-day dosing has an in vitro
release rate corresponding to the following % rate of tramadol
released. TABLE-US-00004 TABLE 4 TIME (H) % RELEASED 1 0-30 2 0-40
3 3-55 8 10-65 12 20-75 16 30-88 24 50-100 36 >80
[0012] More preferably a preparation for once-a-day dosing has an
in vitro release rate substantially as follows. TABLE-US-00005 TIME
(H) % TRAMADOL RELEASED 1 15-25 2 25-35 3 30-45 8 40-60 12 55-70 16
60-75
[0013] Another preferred dissolution rate in vitro upon release of
the controlled release preparation for administration twice daily
according to the invention, is between 5 and 50% (by weight)
tramadol released after 1 hour, between 10 and 75% (by weight)
tramadol released after 2 hours, between 20 and 95% (by weight)
tramadol released after 4 hours, between 40 and 100% (by weight)
tramadol released after 8 hours, more than 50% (by weight) tramadol
released after 12 hours, more than 70% (by weight) released after
18 hours and more than 80% (by weight) tramadol released after 24
hours.
[0014] Furtermore, it is preferred in the case of a controlled
release preparation for administration twice daily that after 8
hours following oral administration between 70 and 95% (by weight)
tramadol is absorbed in vivo, between 77 and 97% (by weight)
tramadol is absorbed after 10 hours and between 80 and 100% (by
weight) tramadol is absorbed after 12 hours.
[0015] A formulation in accordance with the invention suitable for
twice-a-day dosing may have a tmax of 1.5 to 8 hours, preferably 2
to 7 hours, and a W.sub.50 value in the range 7 to 16 hours.
[0016] A formulation in accordance with the invention suitable for
once-a-day dosing may have a tmax in the range of 3 to 6 hours,
preferably 4 to 5 hours and a W.sub.50 value in the range of 10 to
33 hours.
[0017] The W.sub.50 parameter defines the width of the plasma
profile at 50% Cmax, i.e. the duration over which the plasma
concentrations are equal to or greater than 50% of the peak
concentration. The parameter is determined by linear interpolation
of the observed data and represents the difference in time between
the first (or only) upslope crossing and the last (or only)
downslope crossing in the plasma profile.
[0018] The in vitro release rates mentioned herein are, except
where otherwise specified, those obtained by measurement using the
Ph. Eur. Paddle Method at 100 rpm in 900 ml 0.1 N hydrochloric acid
at 37.degree. C. and using UV detection at 270 nm.
[0019] The in vitro absorption rate is determined from measurement
of plasma concentration against time using the deconvolution
technique. A conventional release tramadol drop preparation (Tramal
(trade mark), Grunenthal) was used as the weighting-function and
the elimination half life of tramadol was taken as 7.8 hours.
[0020] The controlled release preparation according to the
invention preferably contains an analgesically effective amount of
tramadol or a pharmaceutically acceptable salt thereof,
conveniently in the range of from 50 to 800 mg, especially 100,
200, 300, 400 to 600 mg (calculated as tramadol hydrochloride) per
dosage unit.
[0021] The controlled release preparation according to the
invention may be presented, for example, as granules, spheroids,
pellets, multiparticulates, capsules, tablets, sachets, controlled
release suspensions, or in any other suitable dosage form
incorporating such granules, spheroids, pellets or
multiparticulates.
[0022] The active ingredient in the preparation according to the
invention may suitably be incorporated in a matrix. This may be any
matrix that affords controlled release tramadol over at least a
twelve hour period and preferably that affords in-vitro dissolution
rates and in vivo absorption rates of tramadol within the ranges
specified above. Preferably the matrix is a controller release
matrix. Alternatively, normal release matrices having a coating
which provides for controlled release of the active ingredient may
be used.
[0023] Suitable materials for inclusion in a controlled release
matrix include [0024] (a) Hydrophillic or hydrophobic polymers,
such as gums, cellulose ethers, acrylic resins and protein derived
materials. Of these polymers, the cellulose ethers, especially
alkylcelluloses are preferred. The preparation may conveniently
contain between 1% and 80% (by weight) of one or more hydrophillic
or hydrophobic polymers. [0025] (b) Digestible, long chain
(C.sub.8-C.sub.50, especially C.sub.12-C.sub.40), substituted or
unsubstituted hydrocarbons, such as fatty acids, fatty alcohols,
glyceryl esters of fatty acids, mineral and vegetable oils and
waxes. Hydrocarbons having a melting point of between 25 and
90.degree. C. are preferred. Of these long chain hydrocarbon
materials, fatty (aliphatic) alcohols are preferred. The
preparation may conveniently contain up to 60% (by weight) of at
least one digestible, long chain hydrocarbon. [0026] (c)
Polyalkylene glycols. The preparation may suitably contain up to
60% (by weight) of one or more polyalkylene glycols.
[0027] One particularly suitable controlled release matrix
comprises one or more alkylcelluloses and one or more
C.sub.12-C.sub.36 aliphatic alcohols. The alkylcellulose is
preferably C.sub.1-C.sub.6 alkyl cellulose, especially ethyl
cellulose. The controlled release preparation according to the
invention preferably contains from 1 to 20% (by weight), especially
from 2 to 15% (by weight) of one or more alkylcelluloses.
[0028] The aliphatic alcohol may conveniently be lauryl alcohol,
myristyl alcohol or stearyl alcohol but is preferably cetyl alcohol
or more preferably cetostearyl alcohol. The controlled release
preparation suitable contains from 5 to 30% (by weight) of
aliphatic alcohol, especially from 10 to 25% (by weight) of
aliphatic alcohol.
[0029] Optionally the controlled release matrix may also contain
other pharmaceutically acceptable ingredients which are
conventional in the pharmaceutical art such as diluents,
lubricants, binders, granulating aids, colourants, flavourants,
surfactants, pH adjusters, anti-adherents and glidants, e.g.
dibutyl sebacate, ammonium hydroxide, oleic acid and colloidal
silica.
[0030] The controlled release preparation according to the
invention may conveniently be film coated using any film coating
material conventional in the pharmaceutical art. Preferably an
aqueous film coating is used.
[0031] Alternatively, the controlled release preparation according
to the invention may comprise a normal release matrix having a
controlled release coating. Preferably the preparation comprises
film coated spheroids containing the active ingredient and a
spheronising agent.
[0032] The spheronising agent may be any suitable pharmaceutically
acceptable material which may be spheronised together with the
active ingredient to form spheroids. A preferred spheronising agent
is microcrystalline cellulose. The microcrystalline cellulose used
may suitably be, for example, Avicel PH 101 or Avicel PH 102 (Trade
Marks, FMC Corporation).
[0033] Optionally the spheroids may contain other pharmaceutically
acceptable ingredients conventional in the pharmaceutical art such
as binders, bulking agents and colourants.
[0034] Suitable binders include water soluble polymers, water
soluble hydroxyalkyl celluloses such as hydroxypropylcellulose or
water insoluble polymers (which may also contribute controlled
release properties) such as acrylic polymers or copolymers for
example ethylcellulose. Suitable bulking agents include
lactose.
[0035] The spheroids are coated with a material which permits
release of the active ingredient at a controlled rate in an aqueous
medium. Suitable controlled release coating materials include water
insoluble waxes and polymers such as polymethacrylates (for example
Eudragit polymers, Trade Mark) or water insoluble celluloses,
particularly ethylcellulose. Optionally, water soluble polymers
such as polyvinylpyrrolidone or water soluble celluloses such as
hydroxypropylmethylcellulose or hydroxypropylcellulose may be
included. Optionally other water soluble agents such as polysorbate
80 may be added.
[0036] Alternatively the drug may be coated onto inert non-pareil
beads and the drug loaded beads coated with a material which
permits control of the release of the active ingredient into the
aqueous medium.
[0037] In a further aspect the present invention provides a process
for preparing a controlled release preparation according to the
present invention comprising incorporating tramadol or a
pharmaceutically acceptable salt thereof in a controlled release
matrix, for example by [0038] (a) granulating a mixture comprising
tramadol or a pharmaceutically acceptable salt thereof and one or
more alkylcelluloses, [0039] (b) mixing the alkylcellulose
containing granules with one or more C.sub.12-.sub.36 aliphatic
alcohols; and optionally [0040] (c) shaping and compressing the
granules, and film coating, if desired; or [0041] (d) granulating a
mixture comprising tramadol or a pharmaceutically acceptable salt
thereof, lactose and one or more alkylcelluloses with one or more
C.sub.12-36 aliphatic alcohol; and, optionally, [0042] (e) shaping
and compressing the granules, and film coating, if desired.
[0043] The controlled release preparation according to the
invention may also be prepared in the form of film coated spheroids
by [0044] (a) granulating the mixture comprising tramadol or a
pharmaceutically acceptable salt thereof and a spheronising agent;
[0045] (b) extruding the granulated mixture to give an extrudate;
[0046] (c) spheronising the extrudate until spheroids are formed;
and [0047] (d) coating the spheroids with a film coat.
[0048] One preferred form of unit dose form in accordance with the
invention comprises a capsule filled with controlled release
particles essentially comprising the active ingredient, a
hydrophobic fusible carrier or diluent and optionally a
hydrophillic release modifier. In particular, the controlled
release particles are preferably prepared by a process which
comprises forming a mixture of dry active ingredient and fusible
release control materials followed by mechanically working the
mixture in a high speed mixer with an energy input sufficient to
melt or soften the fusible material whereby it forms particles with
the active ingredient. The resultant particles, after cooling, are
suitably sieved to give particles having a size range from 0.1 to
3.0 mm, preferably 0.25 to 2.0 mm. An example according to the
invention is described below which is suitable for the commercial
production of dosage units.
[0049] When using such a processing technique it has been found
that, in order most readily to achieve the desired release
characteristics (both in vivo and in vitro as discussed above) the
composition to be processed should comprises two essential
ingredients namely: [0050] (a) tramadol or salt thereof; and [0051]
(b) hydrophobic fusible carrier or diluent; optionally together
with [0052] (c) a release control component comprising a
water-soluble fusible material or a particulate soluble or
insoluble organic or inorganic material.
[0053] We have found that the total amount of tramadol or
pharmaceutically acceptable salt thereof in the composition may
vary within wide limits, for example from 10 to 90% by weight
thereof.
[0054] The hydrophobic fusible component (b) should be a
hydrophobic material such as a natural or synthetic wax or oil, for
example hydrogenated vegetable oil, hydrogenated castor oil,
microcrystalline wax, Beeswax, Carnauba wax or glyceryl
monostearate, and suitably has a melting point of from 35 to
140.degree. C., preferably 45 to 110.degree. C.
[0055] The release modifying component (c), when a water soluble
fusible material, is conveniently a polyethylene glycol and, when a
particulate material, is conveniently a pharmaceutically acceptable
material such as dicalcium phosphate or lactose.
[0056] Another preferred process for the manufacture of a
formulation in accordance with the invention comprises [0057] (a)
mechanically working in a high-speed mixer, a mixture of tramadol
or a pharmaceutically acceptable salt in particulate form and a
particulate, hydrophobic fusible carrier or diluent having a
melting point from 35 to 140.degree. C. and optionally a release
control component comprising a water soluble fusible material, or a
particulate soluble or insoluble organic or inorganic material at a
speed and energy input which allows the carrier or diluent to melt
or soften, whereby it forms agglomerates, [0058] (b) breaking down
the larger agglomerates to give controlled release seeds; and
[0059] (c) continuing mechanically working with optionally a
further addition of low percentage of the carrier or diluent.
[0060] (d) optionally repeating steps (c) and possibly (b) one or
more times.
[0061] This process is capable of giving a high yield (over 80%) of
particles in a desired size range, with a desired uniformity of
release rate of tramadol or salt thereof.
[0062] The resulting particles may be sieved to eliminate any
over-or undersized material then formed into the desired dosage
units by for example, encapsulation into hard gelatin capsules
containing the required dose of the active substance or by
compression into tablets.
[0063] In this method in accordance with the invention preferably
all the tramadol or salt thereof is added in step (a) together with
a major portion of the hydrophobic fusible release control material
used. Preferably the amount of fusible release control material
added in step (a) is between 10% and 90% w/w of the total amount of
ingredients added in the entire manufacturing operation, more
preferably between 20% and 70% w/w.
[0064] Stage (a) of the process may be carried out in conventional
high speed mixers with a standard stainless steel interior, e.g. a
Collette Vactron 75 or equivalent mixer. The mixture is processed
until a bed temperature about 40.degree. C. or above is achieved
and the resulting mixture acquires a cohesive granular texture,
with particle sizes ranging from about 1-3 mm to fine powder in the
case of non-aggregated original material. Such material, in the
case of the embodiments described below, has the appearance of
agglomerates which upon cooling below 40.degree. C. have structural
integrity and resistance to crushing between the fingers. At this
stage the agglomerates are of an irregular size, shape and
appearance.
[0065] The agglomerates are preferably allowed to cool. The
temperature to which it cools is not critical and a temperature in
the range room temperature to 37.degree. C. may be conveniently
used.
[0066] The agglomerates are broken down by any suitable means,
which will commute oversize agglomerates and produce a mixture of
powder and small particles preferably with a diameter under 2 mm.
It is currently preferred to carry out the classification using a
Jackson Crockatt granulator using a suitable sized mesh, or a Comil
with an appropriate sized screen. We have found that if too small a
mesh size is used in the aforementioned apparatus the agglomerates
melting under the action of the beater or impeller will clog the
mesh and prevent further throughput of mixture, thus reducing
yield. A mesh size of 12 has been found adequate.
[0067] The classified material is returned to the high speed mixer
and processing continued. It is believed that this leads to
cementation of the finer particles into particles of uniform size
range.
[0068] In one preferred form of the method of the invention
processing of the classified materials is continued, until the
hydrophobic fusible materials used begin to soften/melt and
optionally additional hydrophobic fusible material is then added.
Mixing is continued until the mixture has been transformed into
particles of the desired predetermined size range.
[0069] In order to ensure uniform energy input into the ingredients
in the high speed mixer it is preferred to supply at least part of
the energy by means of microwave energy.
[0070] Energy may also be delivered through other means such as by
a heating jacket or via the mixer impeller and chopper blades.
[0071] After the particles have been formed they are cooled or
allowed to cool, and may then be sieved to remove any over or
undersized material.
[0072] The resulting particles may be used to prepare dosage units
in accordance with the invention in the form of e.g. tablets or
capsules in manners known per se.
[0073] We have also found that particles containing tramadol or a
salt thereof produced by a melt processing as described in
application PCT/SE93/00225 and the process described and claimed in
our prior unpublished UK application No. 9324045.5 filed on Nov.
23, 1993 as well as the process described herein are particularly
useful for processing into the form of tablets.
[0074] We have found that by suitable selection of the materials
used in forming the particles and in the tabletting and the
proportions in which they are used, enables a significant degree of
control in the ultimate dissolution and release rates of the
tramadol or salt thereof from the compressed tablets.
[0075] Usually, to form a tablet in accordance with the invention,
particles prepared as described above will be admixed with
tabletting excipients e.g. one or more of the standard excipients
such as diluents, lubricants, binding agents, flow aids,
disintegrating agents, surface active agents or water soluble
polymeric materials.
[0076] Suitable diluents are e.g. microcrystalline cellulose,
lactose and dicalcium phosphate. Suitable lubricants are e.g.
magnesium stearate and sodium stearyl fumarate. Suitable binding
agents are e.g. hydroxypropyl methyl cellulose, polyvidone and
methyl cellulose.
[0077] Suitable disintegrating agents are starch, sodium starch
glycolate, crospovidone and croscarmalose sodium. Suitable surface
active are Poloxamer 188[R], polysorbate 80 and sodium lauryl
sulfate. Suitable flow aids are talc colloidal anhydrous silica.
Suitable water soluble polymers are PEG with molecular weights in
the range 1000 to 6000.
[0078] To produce tablets in accordance with the invention,
particles produced in accordance with the invention may be mixed or
blended with the desired excipient(s), if any, using conventional
procedures, e.g. using a Y-Cone or bin-blender and the resulting
mixture compressed according to conventional tabletting procedure
using a suitable size tabletting mould. Tablets can be produced
using conventional tabletting machines, and in the embodiments
described below were produced on standard single punch F3 Manesty
machine or Kilian RLE15 rotary tablet machine.
[0079] Generally speaking we find that even with such a highly
water soluble active agent as tramadol or salt thereof tablets
formed by compression according to standard methods give very low
release rates of the active ingredient e.g. corresponding to
release over a period of greater than 24 hours, say more than 36.
We have found that the release profile can be adjusted in a number
of ways. For instance a higher loading of the drug will be
associated with increased release rates; the use of larger
proportions of the water soluble fusible material in the particles
or surface active agent in the tabletting formulation will also be
associated with a higher release rate of the active ingredient. By
controlling the relative amounts of these ingredients it is
possible to adjust the release profile of the tramadol or salt
thereof.
[0080] In order that the invention may be well understood the
following examples are given by way of illustration only.
BRIEF DESCRIPTION OF THE DRAWINGS
[0081] The present invention is further illustrated with the
accompanying drawings in which:
[0082] FIG. 1 is a graphical depiction of the serum levels of
tramadol following administration of one tablet according to
Example 2 in 12 healthy volunteers; and
[0083] FIG. 2 is a graphical depiction of the plasma profile
resulting from single dose administration of the tablet of Example
8 in comparison to the administration of a commercial preparation
of tramadol drops 100 mg in a trial involving five healthy male
volunteers.
EXAMPLE 1
[0084] Tablets having the following formulation were prepared:
TABLE-US-00006 mg/tablet Tramadol Hydrochloride 100 Lactose Ph.
Eur. 68.0 Ethylcellulose (Surelease .RTM. 25% solids) 15 Purified
Water Ph. Eur. 13.3* Cetostearyl Alcohol Ph. Eur. 42.00 (Dehydag
wax 0) Magnesium Stearate Ph. Eur. 2.00 Purified Talc Ph. Eur. 3.00
230.00 *Removed during processing.
[0085] Tramadol hydrochloride (100 mg) and lactose (68 mg) were
granulated, transferred to a fluid bed granulator and sprayed with
ethylcellulose (15 mg) and water. The granules were then dried at
60.degree. C. and passed through a 1 mm screen.
[0086] To the warmed tramadol containing granules was added molten
cetostearyl alcohol (42 mg) and the whole was mixed thoroughly. The
granules were allowed to cool and sieved through a 1.6 mm screen.
Purified talc and magnesium stearate were added and mixed with the
granules. The granules were then compressed into tablets.
[0087] The tablets were coated with a film coat having the
formulation given below. TABLE-US-00007 mg/tablet
Hydroxypropylmethylcellulose 0.770 Ph. Eur. 15 cps (Methocel E15)
Hydroxypropylmethylcellulose 3.87 (Ph. Eur. 5 cps (Methocel ES)
Opaspray M-1-7111B (33% solids) 2.57 Polyethylene glycol 400 USNF
0.520 Purified Talc Ph. Eur. 0.270 Purified Water Ph. Eur. 55.52*
*Removed during processing.
EXAMPLE 2
[0088] Tablets having the following formulation were prepared:
TABLE-US-00008 mg/tablet Tramadol Hydrochloride 100 Lactose Ph.
Eur. 58.0 Ethylcellulose USNF 15.0 (Ethocel 45 CP) Cetostearyl
alcohol Ph. Eur. 52.00 (Dehydag wax 0) Magnesium Stearate Ph. Eur.
2.00 Purified Talc Ph. Eur. 3.00
[0089] A mixture of tramadol hydrochloride (100 mg), lactose (58
mg) and ethylcellulose (15 mg) was granulated whilst adding molten
cetostearyl alcohol (52 mg) and the whole was mixed thoroughly. The
granules were allowed to cool and sieved through a 1.6 mm screen.
Purified talc and magnesium stearate were added and mixed with the
granules. The granules were then compressed into tablets which were
coated with a film coat having the formulation given in Example
1.
EXAMPLE 3
[0090] Film coated tablets were produced following the procedure
described in Example 2 and having the following formulation:
TABLE-US-00009 mg/tablet Tramadol Hydrochloride 100 Lactose Ph.
Eur. 70.50 Hydroxyethylcellulose Ph. Eur. 12.5 Cetostearyl alcohol
Ph. Eur. 42.00 Magnesium Stearate Ph. Eur. 2.00 Purified Talc Ph.
Eur. 3.00
[0091] In vitro Dissolution Studies
[0092] In vitro dissolution studies were conducted on tablets
prepared as described above. Results are given in Table 1.
TABLE-US-00010 TABLE 1 WT % TRAMADOL RELEASED Time (h) Example 1
Example 2* Example 3 1 39 35 43 2 52 47 60 4 67 62 84 8 82 78 97 12
90 86 -- *Measured on tablet core
[0093] In a trial involving 12 healthy volunteers the serum levels
of tramadol following administration of one tablet according to
Example 2 was found to be as illustrated in FIG. 1.
EXAMPLE 4 and 5
[0094] Particles having the formulations given in Table 11 below,
were prepared by the steps of: [0095] 1. Placing the ingredients
(a) and (c) (total batch weight 0.7 kg) in the bowl of a 10 liter
capacity Collette Gral Mixer (or equivalent) equipped with variable
speed mixing and granulating blades; [0096] ii. Mixing the
ingredients at about 150-1000 rpm whilst applying heat until the
contents of the bowl are agglomerated. [0097] iii. Classifying the
agglomerated material by passage through a Comil and/or Jackson
Crockatt to obtain controlled release seeds. [0098] iv. Warming and
mixing the classified material in the bowl of a 10 liter Collette
Gral, until uniform multiparticulates of the desired pre-determined
size range are formed in yield of greater than 80%. This takes
approximately 5 minutes.
[0099] v. Discharging the multiparticulates from the mixer and
sieving them to separate out the multiparticulates collected
between 0.5 and 2 mm aperture sieves. TABLE-US-00011 TABLE II
Example 4 5 (a) Tramadol HCl (Wt %) 50 75 (b) Hydrogenated
Vegetable Oil (Wt %) 50 25
EXAMPLES 6
[0100] Samples of the particles from Example 4 were blended with
magnesium stearate and purified talc using a Y-Cone or bin-blender.
The blended mixture was then compressed using either (1) 14.times.6
mm, (2) 16.times.7 mm or (3) 18.6.times.7.5 mm capsule shaped
tooling on a single punch F3 Manesty tabletting machine to give
tablets giving 200, 300 and 400 mg of tramadol HCl. The ingredients
per dosage unit amounted to the following: TABLE-US-00012 TABLE III
TABLET MG/TABLET INGREDIENT 1 2 3 Tramadol HCl 200 300 400
Hydrogenated Vegetable Oil 200 300 400 Sub Total 400 600 800
Purified Talc 12.63 18.95 25.26 Magnesium Stearate 8.42 12.63
16.84
[0101] The tablets were assessed by the dissolution using PH, Eur.
Paddle Method I 00 rpm, 0.1 N HCl.
[0102] To assess the non-compressed particles the Ph Eur. Paddle
was replaced by a modified Ph Eur. Basket.
[0103] The results are shown in Table IV below. TABLE-US-00013
TABLE IV HOURS AFTER Particles Tablet 1 Tablet 2 Tablet 3 START OF
TEST % TRAMADOL HCl RELEASED 1 54 16 15 15 2 68 23 20 21 3 76 28 25
25 4 82 32 28 28 6 89 40 35 35 8 93 46 41 40 10 96 50 45 45 12 98
55 49 49 16 100 63 57 56 20 NR 70 63 NR
[0104] These results confirm the effectiveness of the tabletting in
reducing the release rate.
EXAMPLE 7
[0105] Samples of the particles from Example 5 were then tabletted
using a procedure similar to Example 3 and the ingredients per unit
dosage amounted to: TABLE-US-00014 TABLE V TABLET MG/TABLET
INGREDIENT 4 5 6 Tramadol HCl 200 300 400 Hydrogenated Vegetable
Oil 66.7 100 133 Sub Total 266.7 400 533 Purified Talc 7.63 11.44
15.25 Magnesium Stearate 5.16 7.63 10.17
[0106] The tablets and samples of non-compressed multiparticles
(each sample containing 400 mg of tramadol hydrochloride) were
assessed by the dissolution method also described above. The
results are shown in Table VI below: TABLE-US-00015 TABLE VI HOURS
AFTER START OF Particles Tablet 4 Tablet 5 Tablet 6 TEST % TRAMADOL
RELEASED 1 77 43 40 42 2 92 64 55 56 3 98 75 65 66 4 100 83 72 73 6
102 94 83 84 8 102 100 91 91 10 102 NR 96 97
[0107] These results show that by increasing the loading of the
highly water soluble tramadol hydrochloride (75% w/w in this
example compared with 50% w/w in Example 6) a significantly faster
release rate of the active ingredient can be achieved.
EXAMPLE 8
[0108] Example 4 was repeated but with the following formulation:
TABLE-US-00016 Tramadol HCl 200 mg/tablet Hydrogenated Vegetable
Oil 163.0 mg/tablet
[0109] The resulting multiparticulates were blended as described in
Example 6 with the following: TABLE-US-00017 Purified Talc 11.5
mg/tablet Magnesium Stearate 7.66 mg/tablet
[0110] The blend was then compressed as described in Example 6 but
using 15 mm.times.6.5 mm normal concave capsule shaped plain/plain
punches.
[0111] The resulting tablets were then assessed by the dissolution
method described above. The results are shown in Table V.
TABLE-US-00018 HOURS AFTER START OF TEST % TRAMADOL HCl RELEASED 1
20 2 27 3 32 4 37 6 44 8 50 10 55 12 60 16 67 20 73 24 77
[0112] In a trial involving healthy male volunteers the plasma
profile resulting from single dose administrations of the above
tablet are shown in FIG. 2 in comparison to the administration of a
commercial preparation of Tramadol drops 100 mg.
* * * * *